Bio-Path (BPTH) Institutional Ownership $0.14 -0.01 (-3.57%) As of 11:22 AM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Bio-Path (NASDAQ:BPTH)CurrentInstitutional OwnershipPercentage5.74%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$194KNumber ofInstitutional Sellers(last 12 months)0 Get BPTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Bio-Path stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data BPTH Institutional Buying and Selling by Quarter Bio-Path Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024Armistice Capital LLC97,000$194K0.0%N/A4.663% 11/7/2022 Virtu Financial LLC12,090$39K0.0%N/A0.169% 11/7/2022Mount Yale Investment Advisors LLC25,350$81K0.0%N/A0.354% 2/10/2022 Bailard Inc.33,521$126K0.0%N/A0.468% 8/16/2021State Street Corp12,133$81K0.0%N/A0.174% 8/13/2021Northern Trust Corp17,744$119K0.0%N/A0.255% 8/13/2021 Geode Capital Management LLC65,353$435K0.0%+15.5%0.939% 8/13/2021 Vanguard Group Inc.218,992$1.46M0.0%+76.2%3.146% 8/12/2021 Dimensional Fund Advisors LP28,148$188K0.0%+58.8%0.404% 5/21/2021Citadel Advisors LLC20,591$145K0.0%N/A0.296% (Data available from 1/1/2016 forward) BPTH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BPTH shares? During the previous two years, the following institutional investors and hedge funds held shares of Bio-Path shares: Armistice Capital LLC ($194K).Learn more on Bio-Path's institutional investors. What percentage of Bio-Path's stock is owned by institutional investors? 5.74% of Bio-Path's stock is owned by institutional investors. Learn more on BPTH's institutional investor holdings. Which institutional investors have been buying Bio-Path's stock? The following institutional investors have purchased Bio-Path's stock in the last 24 months: Armistice Capital LLC ($97K). How much institutional buying is happening at Bio-Path? Institutional investors have bought a total of 97,000 shares in the last 24 months. This purchase volume represents approximately $194K in transactions. Related Companies INM Major Shareholders ADIL Major Shareholders TCRT Major Shareholders GLTO Major Shareholders CMND Major Shareholders DRMA Major Shareholders ALBT Major Shareholders JAGX Major Shareholders VRAX Major Shareholders EVAX Major Shareholders This page (NASDAQ:BPTH) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access